NLRC5 ELISA Kit Advances Quantification Of Immune Biomarkers
You run the assay, and at first, the numbers look acceptable. When working with an NLRC5 ELISA Kit, this kind of early confidence is...
Eli Lilly GLP-1 Diabetes and Obesity Drug Drive China Pledge
Eli Lilly and Company is indeed a giant in the pharmaceutical industry, and its GLP-1 diabetes and obesity drug franchise has made it even bigger....
TrumpRx Direct-To-Consumer Drug Site Launches in the US
President Donald Trump has unveiled the TrumpRx direct-to-consumer drug site, a government-backed platform aimed at lowering prescription drug costs for Americans willing to pay...
DHL Health Logistics Singapore Invests in €10m Pharma Hub
DHL Group has announced the expansion of DHL Health Logistics Singapore through the development of a €10 million pharmaceutical hub, reinforcing life sciences and...
Lupin and TB Alliance Partner to Advance Telacebec Treatment
Lupin and TB Alliance have entered into a strategic collaboration to advance the clinical development and commercialisation of Telacebec, an investigational drug for the...
NVIDIA and Lilly AI Lab All Set to Transform Drug Discovery
NVIDIA and Eli Lilly and Company have announced the creation of a new NVIDIA-Lilly AI lab, designed to apply artificial intelligence to some of...
Abalone and Pfizer Partner on Rare Activating Antibodies
Abalone Bio, which is a therapeutics biotech company that distinctively measures and also makes utmost use of large-scale activity datasets in order to discover...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...